The multiple myeloma therapeutics pipeline is expected to witness considerable growth in the coming year due to high prevalence of the disease. The growth of multiple myeloma therapeutics pipeline is assisted by targeted therapy and new effective treatment. Also, increased awareness among the population about the various cancer treatments has further fueled the growth of the therapeutics pipeline. Increasing healthcare expenditure and technological advancements are supporting the growth of the therapeutics pipeline for multiple myeloma. An increasing demand for safe and effective medications is also driving the growth of the multiple myeloma therapeutics pipeline. Many government initiatives such as increased funding, designations and grants for speeding up the drug development process has also supported the growth of the therapeutics pipeline.
The National Cancer Institute, which is a part of the U.S. National Institutes of Health, defines multiple myeloma as a cancer that is formed by malignant plasma cells. Normal plasma cells are found in the bone marrow as an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are the main cell types of the human immune system and the major types of lymphocytes are T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also known as immunoglobulins) that help the body attack and kill germs. Lymphocytes are present in many areas of the body, such as lymph nodes, bone marrow, intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue found inside some hollow bones. In addition to plasma cells, the bone marrow has those cells that make the different normal blood cells.
Multiple myeloma is characterized by several symptoms, including low blood count, bone and calcium problem, infections, kidney problems, monoclonal gammopathy, and others. The pipeline of multiple myeloma contains Citarinostat, also known as ACY 24, being developed by Celgene Corporation. It is an orally administered histone deacetylase inhibitor being developed for the treatment of relapsed or refractory multiple myeloma.
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are some of the chemotherapy medication that have been introduced as conventional methods for the treatment of multiple myeloma. However, monoclonal antibodies, immunotherapy, combination therapy and steroids are also showing excellent results for the treatment of the disease.
Many collaborations are in process among various pharmaceutical companies for research and development of multiple myeloma drugs. In May 2016, Acetylon Pharmaceuticals collaborated with New York University School of Medicine to initiate a Phase I trial to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose. Thereafter, the company recommended Phase II dose of citarinostat in combination with ipilimumab and nivolumab for patients with unresectable stage III/stage IV malignant melanoma.
Some of the companies having a pipeline of myeloma therapeutics include Celgene Corporation, Bristol-Myers Squibb, Abbvie, Inc., Novartis AG, F. Hoffman La Roche AG, Amgen, Inc., Karyopharm Therapeutics, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.